Subclinical Thyrotoxicosis and Cardiovascular Risk: Assessment of Circulating Endothelial Progenitor Cells, Proangiogenic Cells, and Endothelial Function

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Aug 4

PMID 35923624

Authors

Jason Phowira

Sherin Bakhashab

Anuradha Doddaballapur

Jolanta U Weaver

Affiliations

Soon will be listed here.

Abstract

Background: Subclinical thyrotoxicosis (SCT) is defined by low or undetectable thyroid-stimulating hormones and normal thyroid hormones. The treatment of SCT is uncertain despite being associated with increased cardiovascular risk (CVR) and mortality. Circulating endothelial progenitor cells (cEPCs) and circulating angiogenic cells (CACs) have been found to be reduced in conditions with CVR. We aimed to evaluate whether endothelial function and cEPC and CAC counts were reduced in SCT and to study the effect of triiodothyronine (T3) on proangiogenic cell (PAC) function from young healthy controls.

Methods: cEPCs (quantified by flow cytometry, 20 SCT/20 controls), CACs following cultures (15 SCT/14 controls), paracrine function of CACs, endothelial function by flow-mediated dilation (FMD, 9 SCT/9 controls), and the effect of T3 on apoptosis and endothelial nitric oxide synthase () expression in PACs were studied.

Results: < 0.001, CD133/VEGFR-2 0.4 (0.0-0.7) vs. 0.6 (0.0-4.6), = 0.009, CD34/VEGFR-2 0.3 (0.0-1.0) vs. 0.7 (0.1-4.9), = 0.002; while CAC count was similar. SCT predicted a lower cEPC count after adjustment for conventional CVR factors. FMD was lower in SCT subjects versus controls (% mean ± SD, 2.7 ± 2.3 vs. 6.1 ± 2.3, = 0.005). studies showed T3 increased early apoptosis and reduced expression in PACs.

Conclusions: In conclusion, SCT is associated with reduced cEPC count and FMD, confirming increased CVR in SCT. Future outcome trials are required to examine if treatment of this subclinical hyperactive state improves cardiovascular outcome.

Clinical Trial Registration: http://www.controlled-trials.com/isrctn/, identifier ISRCTN70334066.

Citing Articles

Cardiovascular outcomes in subclinical thyroid disease: an update.

Ettleson M Curr Opin Endocrinol Diabetes Obes. 2023; 30(5):218-224.

PMID: 37288727 PMC: 10527066. DOI: 10.1097/MED.0000000000000818.

Iodine-Induced Hyperthyroidism and Long-term Risks of Incident Atrial Fibrillation and Flutter.

Inoue K, Guo R, Lee M, Ebrahimi R, Neverova N, Currier J J Clin Endocrinol Metab. 2023; 108(10):e956-e962.

PMID: 37146179 PMC: 10584637. DOI: 10.1210/clinem/dgad250.

References

Hill J, Zalos G, Halcox J, Schenke W, Waclawiw M, Quyyumi A . Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348(7):593-600. DOI: 10.1056/NEJMoa022287. View

Prater D, Case J, Ingram D, Yoder M . Working hypothesis to redefine endothelial progenitor cells. Leukemia. 2007; 21(6):1141-9. DOI: 10.1038/sj.leu.2404676. View

Bulut D, Maier K, Bulut-Streich N, Borgel J, Hanefeld C, Mugge A . Circulating endothelial microparticles correlate inversely with endothelial function in patients with ischemic left ventricular dysfunction. J Card Fail. 2008; 14(4):336-40. DOI: 10.1016/j.cardfail.2007.11.002. View

Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A . Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353(10):999-1007. DOI: 10.1056/NEJMoa043814. View

Parle J, Maisonneuve P, Sheppard M, Boyle P, Franklyn J . Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001; 358(9285):861-5. DOI: 10.1016/S0140-6736(01)06067-6. View

Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U . Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005; 111(22):2981-7. DOI: 10.1161/CIRCULATIONAHA.104.504340. View

Arikan E, Karadag C, Guldiken S . Asymmetric dimethylarginine levels in thyroid diseases. J Endocrinol Invest. 2007; 30(3):186-91. DOI: 10.1007/BF03347423. View

Cikim A, Oflaz H, Ozbey N, Cikim K, Umman S, Meric M . Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. Thyroid. 2004; 14(8):605-9. DOI: 10.1089/1050725041692891. View

Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver J . The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007; 92(5):1715-23. DOI: 10.1210/jc.2006-1869. View

10.

Schmidt-Lucke C, Fichtlscherer S, Aicher A, Tschope C, Schultheiss H, Zeiher A . Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol. PLoS One. 2010; 5(11):e13790. PMC: 2972200. DOI: 10.1371/journal.pone.0013790. View

11.

Ahmed F, Rider R, Glanville M, Narayanan K, Razvi S, Weaver J . Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study. Cardiovasc Diabetol. 2016; 15(1):116. PMC: 5000450. DOI: 10.1186/s12933-016-0413-6. View

12.

Phowira J, Coffey K, Bartholomew P, Vennart N, Moreira M, Emerson H . Radioactive Iodine for the Treatment of Subclinical Thyrotoxicosis Grade 1 and 2: Outcome of up to 18-Year Follow Up. Front Endocrinol (Lausanne). 2022; 13:843857. PMC: 8965555. DOI: 10.3389/fendo.2022.843857. View

13.

Fadini G, Miorin M, Facco M, Bonamico S, Baesso I, Grego F . Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005; 45(9):1449-57. DOI: 10.1016/j.jacc.2004.11.067. View

14.

Wang X, Zeng C, Gong H, He H, Wang M, Hu Q . The influence of nitroglycerin on the proliferation of endothelial progenitor cells from peripheral blood of patients with coronary artery disease. Acta Biochim Biophys Sin (Shanghai). 2014; 46(10):851-8. DOI: 10.1093/abbs/gmu073. View

15.

Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, Nagatsuka K . Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation. 2004; 109(24):2972-5. DOI: 10.1161/01.CIR.0000133311.25587.DE. View

16.

Hristov M, Erl W, Weber P . Endothelial progenitor cells: isolation and characterization. Trends Cardiovasc Med. 2003; 13(5):201-6. DOI: 10.1016/s1050-1738(03)00077-x. View

17.

Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K . Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003; 9(11):1370-6. DOI: 10.1038/nm948. View

18.

Urbich C, Dimmeler S . Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int. 2005; 67(5):1672-6. DOI: 10.1111/j.1523-1755.2005.00261.x. View

19.

Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H . Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001; 89(1):E1-7. DOI: 10.1161/hh1301.093953. View

20.

Collet T, Gussekloo J, Bauer D, den Elzen W, Cappola A, Balmer P . Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012; 172(10):799-809. PMC: 3872478. DOI: 10.1001/archinternmed.2012.402. View